Characteristics and outcomes of Bahraini pediatric patients sent abroad for bone marrow transplantation: A ten-year retrospective cohort study.

Hasan M Isa, Shahd T Bucheeri, Jarrah Y Aldoseri, Ayah A Redha, Abdulla F Mubarak, Shaikha A Altamimi, Ameera A AlOraibi, Mohamed I Alshaikh
{"title":"Characteristics and outcomes of Bahraini pediatric patients sent abroad for bone marrow transplantation: A ten-year retrospective cohort study.","authors":"Hasan M Isa, Shahd T Bucheeri, Jarrah Y Aldoseri, Ayah A Redha, Abdulla F Mubarak, Shaikha A Altamimi, Ameera A AlOraibi, Mohamed I Alshaikh","doi":"10.5500/wjt.v15.i2.100065","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bone marrow transplantation (BMT) is a breakthrough procedure for patients with hematological and oncological conditions, particularly when all other treatments fail. Its indications vary between patients and settings, and its outcomes depend on the donor type, transplantation facility, and center expertise. In countries where transplantation facilities are lacking, sending patients abroad for transplantation might be a safe and effective alternative to leaving the patient to face eventual disease morbidity or even mortality if the procedure is not performed locally. However, studies evaluating BMT abroad are scarce.</p><p><strong>Aim: </strong>To assess the clinical characteristics of patients who underwent BMT overseas and analyze the factors affecting their survival outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of all Bahraini pediatric patients who underwent BMT between 2013 and 2024. Medical records from Salmaniya Medical Complex and Overseas Treatment Office were reviewed. Patient demographics, transplant indications, donor type, transplantation type, overseas centers, complications, and outcomes (overall and 5-year survival rates) were analyzed. Clinical characteristics and outcomes were compared using <i>χ</i> <sup>2</sup> test, Student's <i>t</i>-test, Mann-Whitney <i>U</i> test, and Kaplan-Meier method. Univariate and multivariate analyses were used to estimate survival predictors.</p><p><strong>Results: </strong>Of the 75 listed patients, 62 (82.7%) underwent BMT and were included, 10 (13.3%) did not, and 3 (4.0%) were awaiting transplantation. Most patients were male (<i>n</i> = 33, 53.2%). The mean age at transplantation was 7.8 ± 4.9 years. The main indication for treatment was acute myeloid leukemia (AML) (<i>n</i> = 15, 36.6%). Six patients (9.7%) required re-transplantation. Of the 68 transplants, 60 (88.2%) involved conditioning, mostly a combination of fludarabine and total body irradiation (<i>n</i> = 7, 11.7%). Most patients underwent allogeneic transplantation (<i>n</i> = 48, 77.4%), primarily from related donors (<i>n</i> = 47/48, 97.9%). The most common complication was infection (<i>n</i> = 51, 79.7%). Follow-up averaged 3.3 ± 2.5 years. The overall survival rate was 77.4%. Survival odds were better for non-AML patients and Middle Eastern centers (<i>P</i> = 0.015 and <i>P</i> = 0.032, respectively).</p><p><strong>Conclusion: </strong>Bahraini males with AML primarily underwent allogeneic BMT. Non-AML patients and those transplanted in the Middle East had better survival rates, despite high complication rates.</p>","PeriodicalId":65557,"journal":{"name":"世界移植杂志","volume":"15 2","pages":"100065"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886298/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界移植杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5500/wjt.v15.i2.100065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bone marrow transplantation (BMT) is a breakthrough procedure for patients with hematological and oncological conditions, particularly when all other treatments fail. Its indications vary between patients and settings, and its outcomes depend on the donor type, transplantation facility, and center expertise. In countries where transplantation facilities are lacking, sending patients abroad for transplantation might be a safe and effective alternative to leaving the patient to face eventual disease morbidity or even mortality if the procedure is not performed locally. However, studies evaluating BMT abroad are scarce.

Aim: To assess the clinical characteristics of patients who underwent BMT overseas and analyze the factors affecting their survival outcomes.

Methods: We conducted a retrospective cohort study of all Bahraini pediatric patients who underwent BMT between 2013 and 2024. Medical records from Salmaniya Medical Complex and Overseas Treatment Office were reviewed. Patient demographics, transplant indications, donor type, transplantation type, overseas centers, complications, and outcomes (overall and 5-year survival rates) were analyzed. Clinical characteristics and outcomes were compared using χ 2 test, Student's t-test, Mann-Whitney U test, and Kaplan-Meier method. Univariate and multivariate analyses were used to estimate survival predictors.

Results: Of the 75 listed patients, 62 (82.7%) underwent BMT and were included, 10 (13.3%) did not, and 3 (4.0%) were awaiting transplantation. Most patients were male (n = 33, 53.2%). The mean age at transplantation was 7.8 ± 4.9 years. The main indication for treatment was acute myeloid leukemia (AML) (n = 15, 36.6%). Six patients (9.7%) required re-transplantation. Of the 68 transplants, 60 (88.2%) involved conditioning, mostly a combination of fludarabine and total body irradiation (n = 7, 11.7%). Most patients underwent allogeneic transplantation (n = 48, 77.4%), primarily from related donors (n = 47/48, 97.9%). The most common complication was infection (n = 51, 79.7%). Follow-up averaged 3.3 ± 2.5 years. The overall survival rate was 77.4%. Survival odds were better for non-AML patients and Middle Eastern centers (P = 0.015 and P = 0.032, respectively).

Conclusion: Bahraini males with AML primarily underwent allogeneic BMT. Non-AML patients and those transplanted in the Middle East had better survival rates, despite high complication rates.

巴林儿童患者出国骨髓移植的特点和结果:一项十年回顾性队列研究。
背景:骨髓移植(BMT)是治疗血液病和肿瘤患者的突破性手术,特别是当所有其他治疗都失败时。其适应症因患者和环境而异,其结果取决于供体类型、移植设施和中心专业知识。在缺乏移植设施的国家,将患者送到国外进行移植可能是一种安全有效的替代方法,而不是让患者在当地不进行手术时面临最终的疾病发病率甚至死亡。然而,国外对BMT的评价研究较少。目的:评价国外行BMT患者的临床特点,分析影响其生存结局的因素。方法:我们对2013年至2024年间接受BMT的所有巴林儿科患者进行了回顾性队列研究。审查了Salmaniya医疗中心和海外治疗处的医疗记录。分析患者人口统计学、移植指征、供体类型、移植类型、海外中心、并发症和结局(总生存率和5年生存率)。采用χ 2检验、Student’st检验、Mann-Whitney U检验和Kaplan-Meier法比较临床特征和结局。使用单因素和多因素分析来估计生存预测因子。结果:入选的75例患者中,62例(82.7%)接受了BMT, 10例(13.3%)未接受BMT, 3例(4.0%)等待移植。男性居多(n = 33, 53.2%)。移植时平均年龄为7.8±4.9岁。治疗的主要适应症为急性髓系白血病(AML) (n = 15, 36.6%)。6例(9.7%)患者需要再次移植。在68例移植中,60例(88.2%)涉及调节,主要是氟达拉滨和全身照射联合(n = 7, 11.7%)。大多数患者接受同种异体移植(n = 48, 77.4%),主要来自亲属供体(n = 47/48, 97.9%)。最常见的并发症是感染(n = 51, 79.7%)。平均随访3.3±2.5年。总生存率为77.4%。非aml患者和中东中心的生存率更高(分别为P = 0.015和P = 0.032)。结论:巴林男性AML患者主要接受同种异体骨髓移植。尽管并发症发生率高,但非aml患者和在中东地区移植的患者生存率更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
293
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信